Literature DB >> 33437268

Efficacy of vancomycin in combination with various antimicrobial agents against clinical methicillin resistant Staphylococcus aureus strains.

Gulseren Aktas1.   

Abstract

BACKGROUND: Multi-drug resistant methicillin resistant Staphylococcus aureus (MRSA) strains that have been isolated frequently worldwide have difficulties in the treatment and therefore alternative choices for the treatment of the infections are required. The aim of the study was to evaluate the interaction of various antimicrobials in combination with vancomycin against MRSA.
METHODS: Twenty five clinical MRSA strains isolated in 2016 were included in the study. The interaction between vancomycin and new generation/conventional antimicrobials against MRSA strains was analyzed by E-test.
RESULTS: All of the strains tested was found to be susceptible to vancomycin, telavancin, dalbavancin, ceptobiprole, daptomycin, linezolid, quinupristin-dalfopristin, trimethoprim-sulfamethoxazole, rifampicin and tigecycline. The susceptibility rates of the isolates were found to be high, with the lowest rate (48%) against azithromycin. According to the fractional inhibitory concentration index results, synergistic interaction with vancomycin was determined with trimethoprim-sulfamethoxazole, azithromycin, linezolid, minocycline, dalbavancin, clindamycin in five, three, two, two, one, one and one strain(s), respectively. Additionally, all combinations studied showed additive interaction at high rates.
CONCLUSIONS: The results of the study indicate that the use of vancomycin in combination with conventional and new generation antibiotics is promising. Copyright: © Pakistan Journal of Medical Sciences.

Entities:  

Keywords:  Conventional antibiotics; E-test; MRSA; combination; new generation antibiotics

Year:  2021        PMID: 33437268      PMCID: PMC7794130          DOI: 10.12669/pjms.37.1.2887

Source DB:  PubMed          Journal:  Pak J Med Sci        ISSN: 1681-715X            Impact factor:   1.088


  21 in total

Review 1.  The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.

Authors:  S J van Hal; T P Lodise; D L Paterson
Journal:  Clin Infect Dis       Date:  2012-02-02       Impact factor: 9.079

2.  Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Diagn Microbiol Infect Dis       Date:  2006-01       Impact factor: 2.803

Review 3.  Future trends in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection: An in-depth review of newer antibiotics active against an enduring pathogen.

Authors:  A M Bal; M Z David; J Garau; T Gottlieb; T Mazzei; F Scaglione; P Tattevin; I M Gould
Journal:  J Glob Antimicrob Resist       Date:  2017-07-18       Impact factor: 4.035

4.  Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Authors:  Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

5.  In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.

Authors:  Christophe Isnard; Anne Dhalluin; Damasie Malandain; Quentin Bruey; Michel Auzou; Jocelyn Michon; Jean-Christophe Giard; François Guérin; Vincent Cattoir
Journal:  J Glob Antimicrob Resist       Date:  2018-02-05       Impact factor: 4.035

6.  Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus.

Authors:  Warren E Rose; Peter T Poppens
Journal:  J Antimicrob Chemother       Date:  2008-12-24       Impact factor: 5.790

Review 7.  Combining quinupristin/dalfopristin with other agents for resistant infections.

Authors:  Jack Brown; Burgess B Freeman
Journal:  Ann Pharmacother       Date:  2004-02-27       Impact factor: 3.154

Review 8.  Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.

Authors:  G Cornaglia; G M Rossolini
Journal:  Clin Microbiol Infect       Date:  2009-03       Impact factor: 8.067

9.  In vitro activity effects of combinations of cephalothin, dicloxacillin, imipenem, vancomycin and amikacin against methicillin-resistant Staphylococcus spp. strains.

Authors:  Guadalupe Miranda-Novales; Blanca E Leaños-Miranda; Mariano Vilchis-Pérez; Fortino Solórzano-Santos
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-10-12       Impact factor: 3.944

10.  Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus: consensus by an International Working Group.

Authors:  Mark Wilcox; Suleiman Al-Obeid; Ana Gales; Roman Kozlov; José A Martínez-Orozco; Flavia Rossi; Sergey Sidorenko; Joseph Blondeau
Journal:  Future Microbiol       Date:  2019-02-06       Impact factor: 3.165

View more
  1 in total

1.  An Antisense yycF RNA Modulates Biofilm Organization of Methicillin-Resistant Staphylococcus aureus and Pathogenicity in a Rat Model of Osteomyelitis.

Authors:  Shizhou Wu; Yunjie Liu; Lei Lei; Hui Zhang
Journal:  Antibiotics (Basel)       Date:  2021-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.